- Supported exchanges /
- SHG /
- 603590.SHG
Beijing Konruns Pharmaceutical Co Ltd (603590 SHG) stock market data APIs
Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon acutus hemocoagulase under Suling trade name, a single-component hemocoagulase clinical hemostatic drug for surgical operations. It is also involved in the development of drug candidates, including CX1026 for the treatment of lung, liver, kidney, colon, and skin T lymphocyte cancer; CX1003, which is in phase 1 trial for the treatment of solid tumors/preferably rare tumors; ZY5301 that is in phase 3 clinical trials for the treatment of chronic pelvic pain in sequelae of pelvic inflammatory disease; KC-B173 for bleeding and prevention of bleeding during surgical or invasive procedures; and KC1036, which is in phase 2 clinical trial for the treatment of solid tumors. The company was founded in 2003 and is headquartered in Beijing, China.
Beijing Konruns Pharmaceutical Co Ltd Financial Data Overview
| 25.39 | |
| 25.4 | |
| - | |
| 25.6 | |
| 25.28 | |
| 20.07-38.36 | |
| 4 062 M | |
| 34.7808 | |
| 160 M | |
| 846 M | |
| 0.4295 | |
| 0.428 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Beijing Konruns Pharmaceutical Co Ltd Fundamental Data is available in our Financial Data APIs
- Net Revenue 846 M
- EBITDA 123 M
- Earnings Per Share 0.73
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Beijing Konruns Pharmaceutical Co Ltd Earnings via APIs
- Latest Release 2023-07-31
- EPS/Forecast NaN
Get Beijing Konruns Pharmaceutical Co Ltd End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
